Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 12

Safety And Efficacy Of Princess® FILLER Lidocaine In The Correction Of Nasolabial Folds

Authors Grablowitz D, Sulovsky M, Höller S, Ivezic-Schoenfeld Z, Chang-Rodriguez S, Prinz M

Received 8 April 2019

Accepted for publication 6 October 2019

Published 26 November 2019 Volume 2019:12 Pages 857—864

DOI https://doi.org/10.2147/CCID.S211544

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Doris Grablowitz,1 Monika Sulovsky,2 Sonja Höller,3 Zrinka Ivezic-Schoenfeld,3 Souyet Chang-Rodriguez,3 Martin Prinz3

1Medizinisch Ästhetisches Zentrum Wien, Wien 1010, Austria; 2YUVELL® Fine Aesthetics, Wien 1010, Austria; 3Croma-Pharma GmbH, Leobendorf 2100, Austria

Correspondence: Martin Prinz
Croma-Pharma GmbH, Industriezeile 6, Leobendorf 2100, Austria
Tel +43 2262 684 68-0
Fax +43 2262 684 68-165
Email martin.prinz@croma.at

Purpose: Nasolabial folds (NLFs) are one of the most noticeable signs of facial aging. NLFs negatively affect self-confidence and social acceptance often leading to a person’s desire to improve their appearance using dermal fillers. The hyaluronic acid injectable gel implant Princess® FILLER Lidocaine (PFL) is a minimally invasive easy to administer the product. In this investigation, we assessed the safety and efficacy of PFL to correct moderate to severe NLFs over a 36-week period.
Methods: Adult women and men with moderate to severe NLFs received one injection of PFL to both NLFs. After 2 weeks, a touch-up treatment could be performed, if deemed necessary by the investigator. The change in NLF severity was assessed using the Nasolabial Fold Severity Rating Scale (NFL-SRS) developed by Croma-Pharma and the Global Aesthetic Improvement Scale (GAIS).
Results: Out of 60 analyzed subjects, 59 (98.3%) had improved their NLF severity by at least 1 grade on the NFL-SRS at week 4, 58 subjects (96.7%) at weeks 24 and 36. All subjects showed aesthetic improvement (GAIS), at weeks 4 and 24. The investigator judged the aesthetics as very much improved (score of 1) in 45 (75.0%) at week 4, 48 (80.0%) at week 24, and in 39 of 60 subjects, respectively (65.0%) at week 36. Thirty-six weeks post-initial treatment, 56 of 60 subjects (93.3%) were very satisfied or satisfied with the treatment. Adverse device effects (ADEs) were mild or moderate and resolved at latest 25 days post-onset. The most commonly reported ADEs were injection site hematoma and injection site pain.
Conclusion: PFL was safe and effective in reducing the severity of NLFs. Most subjects were (very) satisfied with the treatment outcome throughout a 36 weeks investigation period.

Keywords: hyaluronic acid, dermal filler, lidocaine hydrochloride, mid to deep dermis, facial wrinkles, injection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]